Facebook

Twitter

scientific
program

 

 

 

Scientific Program cover

2014 Join ACTRIMS-ECTRIMS Meeting Scientific Program (PDF format)

Accreditation Statement and Credit Designation for Physicians  (PDF format)

 

IMPORTANT DATES

31 January 2014 Abstract submission site opens
28 April 2014 Abstract deadline
29 April 2014 Late-breaking abstract submission site opens
30 June 2014 Late-breaking abstract deadline
July 2014 Platform and poster presenters notified
13 September 2014 Best Poster & Best Young Investigator Oral Presentation Awards

 


2014 Joint ACTRIMS-ECTRIMS Meeting CME Needs Assessment (click to view)

 

Scientific Program Themes

  1. Diagnosis, phenotypes, and variants of MS and related disorders
  2. Factors that determine MS susceptibility, disease course, and prognosis: The roles and interactions of genetics, epigenetics, the microbiome, environmental factors, pregnancy, age, comorbidities, and risk behaviors in determining MS susceptibility and disease course
  3. Pathogenesis of MS relapses and progression: the link between inflammation and neurodegeneration
  4. Mechanisms, detection, and significance of gray matter pathology in MS
  5. Methods to monitor MS disease activity and severity: Patient self-report and automated self-assessment, new clinician-reported outcomes, standard and advanced imaging, and biomarkers
  6. Current, emerging, and future disease therapies for relapsing-remitting and progressive MS and related disorders
  7. Treatment strategies: Early treatment, switching therapies, treating-to-target of no evidence of disease activity, personalized treatment, and post-marketing monitoring of safety and efficacy
  8. Regeneration and repair: which strategies look promising and how do we test them
  9. Aspects of trial design in relapsing and progressive MS
  10. Rehabilitative strategies to restore function: Improving cognition, motor function, and mobility
  11. Management of the symptoms and other sequelae of MS
  12. Society and MS: roles of the expert patient, social media, and health policy

 

Scientific Program Learning Objectives

  1. Review the diagnostic criteria, phenotypes, and variants of MS and related disorders to promote more accurate diagnosis and institution of appropriate therapy.
  2. Identify the roles and interactions of genetics, epigenetics, the microbiome, environmental factors, pregnancy, age, comorbidities, and risk behaviors in determining MS susceptibility, disease course, and prognosis to improve understanding of the potential cause and modifiers of the disease.
  3. Integrate information about the overlapping and distinct inflammatory and degenerative mechanisms underlying MS relapses, progression, and white and gray matter pathology as the basis for monitoring and treating the disease.
  4. Summarize methods to monitor MS disease activity and severity, including patient self-report and automated self-assessment, new clinician-reported outcomes, standard and advanced imaging, and biomarkers to optimize their utilization in clinical practice and clinical research.
  5. Synthesize emerging data on treatment strategies, such as early treatment, switching therapies, treating-to-target of no evidence of disease activity, personalized treatment, and post-marketing monitoring of safety and efficacy to more effectively manage disease therapy in practice.
  6. Review the design and results of recent clinical trials in relapsing and progressive MS, including anti-inflammatory, neuroprotective, and repair-promoting strategies, to prepare clinicians for their incorporation into practice in an evidence-based manner.
  7. Integrate treatment of symptoms, multidisciplinary management of the sequelae of MS, and rehabilitative strategies into clinical care to improve patients’ function and quality of life.
  8. Critically examine how the expert patient, news media, social media, and health policy affect the relationships between patients with MS, health care providers, and researchers.

 

Scientific Program

 

Wednesday, 10 September 2014

YI1 – Young Scientific Investigators, Session 1

Chairs: Gilles Edan (FR)
Luanne Metz (CA)

Platform presentations of 6 abstracts

YI2 – Young Scientific Investigators, Session 2

Chairs: Brenda Banwell (US)
Patrick Vermersch (FR)

Platform presentations of 5 abstracts


Thursday, 11 September 2014

PL1 – Plenary Session

Chairs: Suhayl Dhib-Jalbut (US)
Maria Trojano (IT)
Howard Weiner (US)

Speaker: PL1.1 – ACTRIMS-ECTRIMS Opening Lecture: Approaching the Cause of Multiple Sclerosis
David Hafler (US)

Parallel Sessions

PS1 – Cell-based therapies

Chairs: Mark Freedman (CA)
Neil Scolding (GB)

Speakers: PS1.1 – Neural and mesenchymal stem cells
Stefano Pluchino (GB)

PS1.2 – Imaging demyelination and remyelination
Cornelia Laule (CA)

Platform presentations of 3 abstracts

PS2 – MS subpopulations and disease variants

Chairs: Eva Havrdova (CZ)
Miguel Macias (MX)

Speakers: PS2.1 – Radiologically isolated syndrome
Christine Lebrun (FR)

PS2.2 – NMO spectrum disorders
Kazuo Fujihara (JP)

Platform presentations of 3 abstracts

PS3 – MRI

Chairs: Rohit Bakshi (US)
Frederik Barkhof (NL)

Speakers: PS3.1 – Ultra high field MRI
Daniel Reich (US)

PS3.2 – Advanced imaging of the spinal cord
Olga Ciccarelli (GB)

Platform presentations of 3 abstracts

PS4 – EAE and other animal models

Chairs: Amit Bar-Or (CA)
Rhonda Voskuhl (US)

Speakers: PS4.1 – What can EAE teach us about MS
Joan Goverman (US)

PS4.2 – New animal models and human studies are necessary to understand MS
Hans Lassmann (AT)

Platform presentations of 3 abstracts

PS5 – Comorbidities and risk behaviors

Chairs: Samia Khoury (US)
Per Soelberg Sorensen (DK)

Speakers: PS5.1 – Effects of comorbidities and risk behaviors on MS susceptibility and prognosis
Ruth Ann Marrie (CA)

PS5.2 – Leptin and other adipokines in EAE and MS
Anne Cross (US)

Platform presentations of 3 abstracts

PS6 – Risk management with MS therapies

Chairs: Michel Clanet (FR)
Andrew Goodman (US)

Speakers: PS6.1 – PML with natalizumab, fingolimod, and dimethyl fumarate
Ralf Gold (DE)

PS6.2 – Rebound after natalizumab discontinuation
Bruce Cree (US)

Platform presentations of 3 abstracts

Hot Topics

HT1 – Genetics of MS

Chairs: Philip de Jager (US)
Tomas Olsson (SE)

Speakers: HT1.1 – Genetics of adult-onset MS
Ingrid Kockum (SE)

HT1.2 – Genetics of pediatric onset MS
Lisa Barcellos (US)

Platform presentation of 1 abstract

HT2 – New routes of drug development

Chairs: Michael Hutchinson (IE)
Robert Naismith (US)

Speakers: HT2.1 – Repurposing drugs
Klaus Schmierer (GB)

HT2.2 – Generic drugs
Jeffrey Cohen (US)

Platform presentation of 1 abstract

HT3 – Symptomatic and rehabilitation strategies

Chairs: Christopher Bever (US)
Alan Thompson (GB)

Speakers: HT3.1 – Cognitive impairment in early MS and cognitive rehabilitation
Maria Pia Amato (IT)

HT3.2 – Cannabinoids as symptomatic and neuroprotective therapy
Cris Contantinescu (GB)

Platform presentation of 1 abstract


Friday, 12 September 2014

Free Communications

FC1 – Free Communication 1

Chairs: Giancarlo Comi (IT)
Tanuja Chitnis (US)

Platform presentations of 4 abstracts

FC2 – Free Communication 2

Chairs: Paul O’Connor (CA)
Mar Tintore (ES)

Platform presentations of 4 abstracts

FC3 – Free Communication 3

Chairs: Devon Conway (US)
Krzystof Selmaj (PL)

Platform presentations of 4 abstracts

Parallel Sessions

PS7 – Biomarkers

Chairs: Bernard Hemmer (DE)
V Wee Yong (CA)

Speakers: PS7.1 – Oxysterols and cholesterol precursors as biomarkers of neurodegeneration
Charlotte Teunissen (NL)

PS7.2 – Biomarkers of treatment response to MS disease therapies
Suhayl Dhib-Jalbut (US)

Platform presentations of 3 abstracts

PS8 – Assessing neuroprotection

Chairs: David Miller (GB)
Emmanuelle Waubant (US)

Speakers: PS8.1 – Imaging in neurodegenerative disorders
Matilde Inglese (US)

PS8.2 – Update on completed and ongoing neuroprotection and repair trials
Jeremy Chataway (GB)

Platform presentations of 3 abstracts

PS9 – Treatment strategies in clinical practice

Chairs: Aaron Miller (US)
Takahiko Saida (JP)

Speakers: PS9.1 – Is no evidence of disease activity a realistic treatment target?
Hans Peter Hartung (DE)

PS9.2 – Treatment algorithms in patients with ongoing disease activity
Xavier Montalban (ES)

Platform presentations of 3 abstracts

PS10 – Immune mechanisms

Chairs: Ariel Miller (IL)
Alexandre Prat (CA)

Speakers: PS10.1 – microRNA and autoimmunity
Howard Weiner (US)

PS10.2 – Fibrin and microglia in MS
Katerina Akassoglou (US)

Platform presentations of 3 abstracts

PS11 – Gray matter pathology and mechanisms of progression

Chairs: Wolfgang Bruck (DE)
Robert Fox (US)

Speakers: PS11.1 – Heterogeneity and significance of gray matter pathology
Jeroen Geurts (NL)

PS11.2 – Is primary progressive MS a distinct disease
Sandra Vukusic (FR)

Platform presentations of 3 abstracts

PS12 – Study design and endpoints

Chairs: Myla Goldman (US)
Ludwig Kappos (CH)

Speakers: PS12.1 – Patient-centered care: patient-reported health status and self-administered performance testing
Richard Rudick (US)

PS12.2 – Pragmatic clinical trials and registry studies
Maria Trojano (IT)

Platform presentations of 3 abstracts

Hot Topics

HT4 – Remyelination

Chairs: Tanja Kuhlmann (DE)
Samuel Ludwin (CA)

Speakers: HT4.1 – Epigenome-wide studies: what can we learn from them?
Patrizia Casaccia (US)

HT4.2 – Strategies to augment remyelination
Catherine Lubetski (FR)

Platform presentation of 1 abstract

HT5 – Inflammation and neurodegeneration

Chairs: Jack Antel (CA)
Vijay Kuchroo (US)

Speakers: HT5.1 – Metabolomics, mitochondria, and energy imbalance in MS
Peter Calabresi (US)

HT5.2 – Parasitic infections and MS
Jorge Correale (AR)

Platform presentation of 1 abstract

HT6 – Society and MS

Chairs: Fiona Costello (CA)
Gavin Giovannoni (GB)

Speakers: HT6.1 – The interaction between the media, social media, advocacy, science, and medicine
Michael Rasminsky (CA)

HT6.2 – Patients as partners in clinical research
Paul Wicks (US)

Platform presentation of 1 abstract


Saturday, 13 September 2012

LB1 – Late Breaking News

Chairs: Bernard Uitdehaag (NL)
Jerry Wolinsky (US)

Platform presentations of 6 abstracts

PL2 – Plenary Session

Chairs: Jeffrey Cohen (US)
Xavier Montalban (ES)

Speaker: PL2.1 – Paty Lecture: Neuroprosthetics for paralysis
Andrew Schwartz (US)

Speaker: PL2.2 – ACTRIMS-ECTRIMS Clinical Research Highlights
Ellen Mowry (US) and Robert Bermel (US)

Speaker: PL2.3 – ACTRIMS-ECTRIMS Basic Research Highlights
Finn Sellebjerg (DK) and Fredrik Piehl (SE)


Speakers

Argentina
Jorge Correale

Austria
Hans Lassmann

Canada
Cornelia Laule
Ruth Ann Marrie
Michael Rasminsky

Denmark
Finn Sellebjerg

France
Christine Lebrun
Catherine Lubetski
Sandra Vukusic

Germany
Ralf Gold
Hans Peter Hartung

Italy
Maria Pia Amato
Maria Trojano

Japan
Kazuo Fujihara

Netherlands
Jeroen Geurts
Charlotte Teunissen

Spain
Xavier Montalban

Sweden
Ingrid Kockum
Fredrik Piehl

United Kingdom
Jeremy Chataway
Olga Ciccarelli
Cris Contantinescu
Stefano Pluchino
Klaus Schmierer

United States
Katerina Akassoglou
Lisa Barcellos
Robert Bermel
Peter Calabresi
Patrizia Casaccia
Jeffrey Cohen
Bruce Cree
Anne Cross
Suhayl Dhib-Jalbut
Joan Goverman
David Hafler
Matilde Inglese
Ellen Mowry
Daniel Reich
Richard Rudick
Andrew Schwartz
Howard Weiner
Paul Wicks


Chairpersons

Canada
Jack Antel
Amit Bar-Or
Fiona Costello
Mark Freedman
Samuel Ludwin
Luanne Metz
Paul O’Connor
Alexandre Prat
V Wee Yong

Czech Republic
Eva Havrdova

Denmark
Per Soelberg-Sorensen

France
Michel Clanet
Gilles Edan
Patrick Vermersch

Germany
Wolfgang Bruck
Bernhard Hemmer
Tanja Kuhlmann

Ireland
Michael Hutchinson

Israel
Ariel Miller

Italy
Giancarlo Comi
Maria Trojano

Japan
Takahiko Saida

Mexico
Miguel Macias

Netherlands
Frederik Barkof
Bernhard Uitdehaag

Poland
Krzystof Selmaj

Spain
Xavier Montalban
Mar Tintore

Sweden
Tomas Olsson

Switzerland
Ludwig Kappos

United Kingdom
Gavin Giovannoni
David Miller
Neil Scolding
Alan Thompson

United States
Brenda Banwell
Rohit Bakshi
Christopher Bever
Tanuja Chitnis
Jeffrey Cohen
Devon Conway
Philip de Jager
Suhayl Dhib-Jalbut
Robert Fox
Myla Goldman
Andrew Goodman
Samia Khoury
Vjay Kuchroo
Aaron Miller
Robert Naismith
Rhonda Voskuhl
Emmanuelle Waubant
Howard Weiner
Jerry Wolinsky

 

 

 

ACTRIMS SECRETARIAT

For more information on the program, support opportunities, or any general questions, please contact the ACTRIMS Secretariat.

ACTRIMS
22 North Carroll Street, Suite 300
Madison, Wisconsin 53703 USA

+ 1 608 310 8960
info@actrims.org

Logistics Secretariat

For more information about housing, registration, press, media and Boston in general, please contact the Logistics Secretariat.

c/o Opus 3 inc.
417 Saint-Pierre Street, Suite 302
Montréal QC H2Y 2M4 Canada

+ 1 514 395 1808
info@msboston2014.org

opus logo